Now Available! Lentiviral vector T cell targeting reagents

Imanis Life Sciences

Menu

Cellective

The Cellective Targeting System is an advanced lentiviral vector (LV) delivery platform enabling user-defined cell transduction. Cellective overcomes hurdles with delivery to challenging cellular targets and limits unwanted off-target transduction while maintaining all the key benefits of lentiviral vectors including large cargo capacity and simple manufacture. For both in vitro and in vivo applications, reach your intended target with the Cellective Targeting System.

See Our Product Offerings

 

How it Works:


Cellective reagents enable manufacture of lentiviral vectors targeted to user-selected cellular receptors. The modular system is comprised of a programmable G-fusogen, which is used to pseudotype LVs, and targeting adapters, which covalently bind and program the G-fusogen to specific cellular receptors. Targeting adapters are currently available for targeting CD3 on T cells.

 

Precision Targeting:


Cellective enables precision transduction of target cells, reducing biological noise, simplifying the study of target cells, improving experimental repeatability, and strengthening study conclusions. In addition, Cellective can overcome hurdles with co-culture models, and amplify mechanistic conclusions when studying signaling, resistance, and tumor microenvironment.

 

 

Cellective LVs encoding GFP and labeled with the CD3 Targeting Adapter efficiently transduce CD3+ Jurkat cells with minimal transduction of CD3- Jurkat-TCR-KO cells compared to traditional VSV-G pseudotyped LVs.

 

 

 

 

Improved Transduction Capabilities:


Cellective makes it easier to transduce hard to transduce cell lines, including primary immune cells (PBMCs).

 

Un-activated PBMCs were efficiently transduced with Cellective LVs targeted with the CD3 Targeting Adapter, but not with untargeted Cellective LV control. Transduction efficiency with CD3-targeted Cellective LV was 3-fold higher than with a traditional VSV-G LV.

 

 

 

Fail-safe CD3 Targeting:


Precision T cell transduction is a key element of the Cellective system with the current CD3 Targeting Adapter. Following packaging, LVs are mixed with Targeting Adapter, yielding ready-to-use fully pseudotyped LVs. Assembly of the Targeting Adapter and programable G-fusogen has been extensively optimized and is highly efficient. Even in cases where sub-optimal assembly takes place, the fail-safe design of the Cellective system ensures only target cells can be transduced.

 

 

 

In the absence of Targeting Adapter, Cellective LVs demonstrate minimal background transduction on cells compared to a traditional VSV-G pseudotyped control LV.

 

 

 

 

How to Use: 


Products

 
 

Product Offerings:


The Imanis Cellective LV Targeting System is a collection of reagents used to generate lentiviral vectors (LV) targeted to specific cellular receptors. The system has three core components:

LV Packaging Mix and Targeting Adapters are available for purchase individually or together as a Cellective LV Targeting Kit which also includes a GFP reporter LV Transfer Plasmid control. Available sizing facilitates a broad range of in vitro- and in vivo-scale applications.

Product Catalog Number Price Purchase
Cellective LV CD3 Targeting Kit- Small ICT-LTK-S $1,090 Add Item
Cellective LV CD3 Targeting Kit- Medium ICT-LTK-M $2,750 Add Item
Cellective LV CD3 Targeting Kit- Large ICT-LTK-L $6,875 Add Item
Cellective LV Packaging Mix- Small ICT-LPM-S $595 Add Item
Cellective LV Packaging Mix- Medium ICT-LPM-M $1,500 Add Item
Cellective LV Packaging Mix- Large ICT-LPM-L $3,750 Add Item
Cellective CD3 Targeting Adapter- Small ICT-TAC3-S $495 Add Item
Cellective CD3 Targeting Adapter- Medium ICT-TAC3-M $1,250 Add Item
Cellective CD3 Targeting Adapter- Large ICT-TAC3-L $3,125 Add Item
User Manual

Cellective is a flexible platform that allows unique cellular receptors and unique cell types to be readily transduced by selecting an alternative Targeting Adapter. Alternative Targeting Adapters are currently under development. Contact us if you have a specific target in mind.

Learn More